We Value Your Input

In 2022, we launched the CAR-T Connection newsletter. The intent of the publication is to capture the Janssen Advanced Therapies CAR-T E2E Supply Chain journey and connects the activities of manufacturing and supply chain to Global Commercial. The CAR-T Connection complements our other publications by providing a more in-depth view of operations and the successes achieved by the Advanced Therapies CAR-T Supply Chain global team and our alliance partner, Legend Biotech.

Thank you for taking the time to provide your feedback!
1.Please select your company.(Required.)
2.Please select the Region in which you are located.(Required.)
3.Please select your function(Required.)
4.How thoroughly do you read the CAR-T Connection newsletter?(Required.)
5.How much time do you estimate you cumulatively spent reading and viewing the CAR-T Connection per issue?(Required.)
6.How valuable did you find the CAR-T Connection newsletter content?(Required.)
1 - Not Valuable
2 - Somewhat Valuable
3 - Neutral
4 - Valuable
5 - Very Valuable
7.How satisfied are you with the timeliness of the content presented in the CAR-T Connection?(Required.)
1 - Very Dissatisfied
2 - Dissatisfied
3 - Neutral
4 - Satisfied
5 - Very Satisfied
8.Has the content in the CAR-T Connection helped you better engage with your team and/or introduced you to new sites and activities you previously were not aware of?(Required.)
1 - Never
2 - Rarely
3 - Occasionally
4 - Significantly
9.Which sections of the newsletter do you enjoy and are most applicable to gaining the most information and impact?(Required.)
Low
Moderate
High
ALL IN Leadership Update
On-Site Insights
ONE TEAM: People on the Move
Employee Spotlight
Vein to Vein
A Closer Look
Culture Grows Our CAR-T Community/ Credo Activities
Logistically Speaking
Consistency Counts
The News Stream
Regional Recap
Out Front Leadership Laboratory Updates
10.The ALL IN section at the beginning of the CAR-T Connection newsletter provides thoughts from our senior leaders on the state of supply chain activities. How satisfied are you with the updates provided? (Required.)
1 - Very Dissatisfied
2 - Dissatisfied
3 - Neutral
4 - Satisfied
5 - Very Satisfied
11.After reading the CAR-T Connection newsletter, which of the following emotions would best describe how you feel about working on the launch and expansion of CARVYKTI across the regions? (Select all that apply)(Required.)
12.How would you rate the CAR-T Connection's ability to communicate Janssen's and Legend Biotech's efforts and activities across E2E Supply Chain and Commercial as it relates to:(Required.)
1 - Not Enough Coverage
2 - Right Amount of Coverage
5 - Too Much Coverage
Unity of Alliance (Janssen & Legend Biotech)
Coverage balance amongst Raritan Plant activities
Coverage balance amongst Regional Commercial activities
Coverage balance amongst Global Supply Chain sites
13.Please provide any additional feedback on your experience with the CAR-T Connection and potential ways we may be able to improve our publication.
14.Which other Janssen Supply Chain Advanced Therapies or CAR-T newsletters do you read? (Select all that apply)
15.Have you subscribed to the JSC Advanced Therapies Yammer site?